Reported Adverse Effects of Electronic Cigarettes

Aug.22.2022
Reported Adverse Effects of Electronic Cigarettes
UK drug regulators received 200 reports of 556 different side effects in e-cigarette users, including fatigue, blurred vision, and constipation.

The drug regulatory agency has reported that smokers have complained that their devices leave them exhausted, with blurry vision or constipation.


The medical regulatory agency has received around 200 reports from individuals who have experienced 556 different side effects. This information comes from Getty and covers the past three years.


One user complained of having hearing issues, while another claimed that these small items had left a ringing sound in their ears.


The Administration of Drug and Healthcare Products has stated that the most common complaints include coughing, hiccupping, sore throat or hoarseness, and wheezing.


More unusual issues include two cases of dizziness - where the room spins - and three instances of blurry vision or teary eyes.


One person complains that they are tired from using electronic cigarettes, while another says that the devices make them feel lazy.


Approximately 3 million people in the United Kingdom use electronic cigarettes.


John Dunne, Chairman of the UK Vaping Industry Association, has stated that the harm caused by e-cigarettes is significantly less than that of smoking.


He added, "It is well known that adult smokers may experience side effects when transitioning from smoking to physically adapting to cessation.


The regulatory body stated that "reporting of adverse reactions does not necessarily mean that they are caused by e-cigarettes.


Statement:


This article is compiled from third-party information and is intended for industry professionals to share and learn from.


This article does not represent the views of 2FIRSTS and we are unable to confirm the authenticity and accuracy of its content. The translation of this article is intended for internal industry exchange and research purposes only.


Due to limitations in the translating ability, this article may not fully convey the exact meaning of the original text. Please refer to the original text for accurate information.


2FIRSTS maintains complete alignment with the Chinese government on all domestic, Hong Kong/Macau/Taiwan-related and foreign-related statements and positions.


All compiled information is copyright of the original media and author. If there is any infringement, please contact us for deletion.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Singapore to Extend Etomidate Controls and Table New Vape Legislation in 2026
Singapore to Extend Etomidate Controls and Table New Vape Legislation in 2026
Singapore will maintain etomidate’s classification under drug control laws while preparing new legislation targeting e-vaporisers, as authorities reinforce a hardline regulatory stance on vaping.
Feb.05
The Volume Illusion: Measuring the Future of Nicotine with the Tools of the Past
The Volume Illusion: Measuring the Future of Nicotine with the Tools of the Past
As next-generation nicotine products become economically central rather than marginal, traditional volume-based metrics are increasingly unable to explain consumption, risk, and value. Units designed for a cigarette-based economy struggle to describe systems defined by delivery speed, pharmacokinetics, and adaptive user behavior. Drawing on financial reporting, regulation, and nicotine science, a fundamental question: can the future of nicotine still be measured using the tools of its past?
Feb.09 by Alan Zhao | 2Firsts Perspectives
KT&G to cancel 10.866 mln treasury shares, about 9.5% of shares outstanding
KT&G to cancel 10.866 mln treasury shares, about 9.5% of shares outstanding
KT&G said it plans to cancel all treasury shares it holds, totaling 10,866,189 shares, representing about 9.5% of shares outstanding, in line with Korea’s third amendment to the Commercial Act requiring companies to cancel repurchased shares within one year. The company also disclosed progress on its shareholder-return plan and multiple agenda items for next month’s shareholders meeting.
Feb.26
Morocco rolls out compulsory rules for e-cigarettes, muassel and nicotine pouches
Morocco rolls out compulsory rules for e-cigarettes, muassel and nicotine pouches
Starting February 2026, Morocco will apply its first mandatory standard governing “smoke-free” products—covering e-cigarettes, muassel and nicotine pouches. Drafted by IMANOR, the standard introduces detailed requirements on composition, labelling, traceability and safety, and will apply to imported products. Consumer advocates say clear labelling and traceability are essential, while urging stronger public-awareness efforts and resources.
Feb.03 by 2FIRSTS.ai
Kansas Senate approves tougher vape rules to target unlicensed products and child-directed ads
Kansas Senate approves tougher vape rules to target unlicensed products and child-directed ads
The Kansas Senate approved Senate Bill 355 on Wednesday, aiming to crack down on unlicensed vaping products and eliminate advertisements geared toward children. The bill, backed by major tobacco companies, would impose the same licensing and advertising requirements on e-cigarettes as other nicotine products and require every e-cigarette manufacturer doing business in Kansas to obtain a license, with a $2,500 application fee.
Feb.13 by 2FIRSTS.ai
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24